Pipelines for NewCo & Licensing
Welcome to Unibest's Pipeline Insights, your gateway to cutting-edge pharmaceutical innovation. In this blog collection, we unveil our open pipelines for NewCo development and licensing opportunities, offering valuable insights into promising molecular targets, innovative drug candidates, and the diseases we aim to conquer. Whether you're a potential partner, investor, or industry enthusiast, explore how Unibest is shaping the future of medicine through groundbreaking research and collaborative opportunities. Dive into our collection to discover how we're working to transform patient care and contribute to global health improvements, one pipeline at a time.

AdV.jpg
Understanding Oncolytic Viruses and UB084 for Global Partnership

This article explores the intersection of virology and oncology, examining how scientists harness viruses' natural abilities to combat cancer. Unibest is pleased to present an oncolytic virus asset, currently in Phase II trials, that is open for global licensing and co-development opportunities.

READ MORE
ShK and Kv13 blocking polypeptides as potential therapeutic agents for neuroinflammatory diseases.png
Kv1.3 Inhibitors: Breakthrough Treatments for Autoimmune Disorders - What You Need to Know

The Kv1.3 channel, a classical Shaker-type potassium channel, holds a unique place in cellular biology. Unibest presents two Kv1.3 inhibitor assets, UB024 and UB029, for NewCo and License opportunities.

READ MORE
screenshot-20250421-140352.png
Unibest Unveils Innovative 505(b)(2) Project for Semaglutide: UB104

In the ever-evolving landscape of pharmaceutical innovation, Unibest is proud to announce a groundbreaking development in the administration of Semaglutide, codenamed UB-PEP-104.

READ MORE
1NKP.png
Targeting c-Myc and a Molecular Glue: UB025

The transcription factor c-Myc has emerged as a critical target in oncology, given its aberrant expression in more than 70% of human cancers. Unibest presents a first-in-class small molecule glue targeting c-Myc open for NewCo.

READ MORE
Reteplase vs Alteplase - Rankin Scale.jpg
Reteplase: A Proven Superior Thrombolytic Agent for Acute Ischemic Stroke

We, Unibest, are excited to share with you the remarkable benefits and opportunities that Reteplase brings to the global market.

READ MORE
IL-11, reteplase and EPO.png
Three Recombinant Protein Products for Global Licensing

Unibest is proud to partner with a renowned Chinese Pharmaceutical company and announce the following global licensing opportunities:1.

READ MORE
rhEPO product.png
rhEPO: From Biochemistry To Commercial

Thrombolytic drugs play a crucial role in treating various venous and arterial thromboembolic conditions, particularly acute myocardial infarction.

READ MORE